Discovery of Functional Antibody Leads at Early Stage of Lead Screening

Currently, most therapeutic antibody discovery strategies start by screening for binders, followed by purification of these antibodies for further functional characterization. However, massive resources are invested into the time-consuming step-by-step screening schema, and arbitrary selection of candidates purely based on binding capability further compromises diversity.

In this white paper, we will discuss solutions that can be applied to current antibody discovery platforms to overcome this issue and significantly improve process efficiency.

  • Discovery of Functional Antibody Leads at Early Stage of Lead Screening
  • COVERED IN THIS WHITE PRPER

    • What is the current bottleneck in therapeutic antibody discovery?
    • How to discover functional leads via different antibody generation platforms?
      • hybridoma platform
      • single B cell platform
      • phage display platform
    • How to select a suitable partner to discover functional leads?